Drug intelligence / Profile preview

WO2023273762

Development stage: Preclinical
Lead developer: Fundamenta Therapeutics
Modality: Cell Therapies
Administration: Intravenous

Overview

WO2023273762 refers to a patent-associated cell therapy technology developed by Fundamenta Therapeutics that targets the CD3 epsilon (CD3ε) subunit of the T-cell receptor complex. This technology is designed for the treatment of hemic and lymphatic diseases, such as hematological malignancies. While specific details regarding the exact cellular construct (e.g., CAR-T or TCR-T) are not fully disclosed in public pipeline summaries, the approach likely involves leveraging CD3ε to facilitate T-cell activation or redirection against malignant cells. The asset is currently in the discovery or preclinical stage of development.

Other names: Fundamenta Therapeutics CD3ε cell therapyCD3ε-targeted cell therapy

Beyond the preview

Go deeper on WO2023273762.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on WO2023273762.

Explore the full profile